Literature DB >> 16273219

An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.

Pedro Miguel Lacal1, Federica Ruffini, Elena Pagani, Stefania D'Atri.   

Abstract

The vascular endothelial growth factor-A (VEGF-A) is a cytokine that promotes angiogenesis through the activation of two tyrosine kinase receptors, VEGFR-1 and VEGFR-2, on vascular endothelial cells. Moreover, several experimental evidences indicate that VEGF-A may also play a role in tumor progression by acting on neoplastic cells expressing VEGFRs. In this study we show that human melanoma cells that simultaneously produce VEGF-A and express VEGFRs exhibit a higher spontaneous ability to invade the extracellular matrix (ECM) than melanoma cells not expressing either VEGF-A or VEGFRs. Exposure of VEGFR expressing melanoma cells to exogenous VEGF-A further increases their ability to invade the ECM. Moreover, an inhibitor of VEGFR tyrosine kinase activity is able to abrogate VEGF-A-induced stimulation of ECM invasion. A cell clone (13443/N2) derived from a VEGF-A responsive melanoma cell line and expressing high levels of VEGFR-2 invades the ECM eight-fold more efficiently than a cell clone derived from the same cell line and expressing extremely low levels of the receptor. Exposure of 13443/N2 cells to VEGF-E, which selectively binds and activates VEGFR-2, increases their ability to invade the ECM. Finally, the expression of the VEGF-A mRNA antisense sequence in 13443/N2 cells markedly reduces the release of VEGF-A and ECM invasion. In conclusion, our data show for the first time that a VEGF-A-driven autocrine loop promotes human melanoma cell ability to invade the ECM, and strongly support the hypothesis that activation of VEGFR-2 plays a primary role in this process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273219

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.

Authors:  Xue-fen Wang; Ling-fang Tu; Li-hong Wang; Jian-ying Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-10       Impact factor: 3.066

2.  Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

Authors:  Marcella Marcellini; Naomi De Luca; Teresa Riccioni; Alessandro Ciucci; Angela Orecchia; Pedro Miguel Lacal; Federica Ruffini; Maurizio Pesce; Francesca Cianfarani; Giovanna Zambruno; Augusto Orlandi; Cristina Maria Failla
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

Authors:  V Cesarini; E Guida; F Todaro; S Di Agostino; V Tassinari; S Nicolis; R Favaro; S Caporali; P M Lacal; E Botti; A Costanzo; P Rossi; E A Jannini; S Dolci
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

5.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

6.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  Molecular mechanisms of resistance to tumour anti-angiogenic strategies.

Authors:  Renaud Grépin; Gilles Pagès
Journal:  J Oncol       Date:  2010-03-09       Impact factor: 4.375

8.  EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Authors:  Faten Bougatef; Suzanne Menashi; Farah Khayati; Benyoussef Naïmi; Raphaël Porcher; Marie-Pierre Podgorniak; Guy Millot; Anne Janin; Fabien Calvo; Céleste Lebbé; Samia Mourah
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

Review 9.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

10.  Current concepts of metastasis in melanoma.

Authors:  Blazej Zbytek; J Andrew Carlson; Jacqueline Granese; Jeffrey Ross; Martin C Mihm; Andrzej Slominski
Journal:  Expert Rev Dermatol       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.